Evidence map›Paper›PMID 37576965›Full record

ReviewFrontiers in endocrinology2023

The complex pathophysiology of bone fragility in obesity and type 2 diabetes mellitus: therapeutic targets to promote osteogenesis.

Siresha Bathina, Reina Armamento-Villareal

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03887936 (Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03887936 phase4completednot on this map

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2019 to 2025Enrolled92ConditionsType 2 Diabetes Mellitus, HypogonadismArmsTestosterone gel 1.62%, Placebo
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Differences and similarities in cortical bone of the femur between donors with and without type 2 diabetes.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Article
  5. [A Study on the Relationship Between Cyclic Inflammatory Protein Fibroblast Growth Factor 21, Osteoporosis, and Fractures].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  6. PasteurizedFrontiers in immunology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Bone health in children and adolescents with type 1 and type 2 diabetes.Annals of pediatric endocrinology & metabolism · 2025
    Article
  12. Role of Body Fat and Metabolic Rate in Site-Specific Fracture Risk: A 20-Year Taiwanese Cohort Study.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Siresha BathinaDivision of Endocrinology Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, United States.
Reina Armamento-VillarealDivision of Endocrinology Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, United States.
Michael E. DeBakey VA Medical Center · US

Funding

Aromatase Inhibitors and Weight Loss in Severely Obese Men with HypogonadismR01HD093047 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI VILLAREAL, REINA C · 2017 to 2022
$1.9M
CSRD VA I01 CX001665NICHD NIH HHS R01 HD093047
6 · The paper itself

Abstract

Fractures associated with Type2 diabetes (T2DM) are major public health concerns in an increasingly obese and aging population. Patients with obesity or T2DM have normal or better than normal bone mineral density but at an increased risk for fractures. Hence it is crucial to understand the pathophysiology and mechanism of how T2DM and obesity result in altered bone physiology leading to increased fracture risk. Although enhanced osteoclast mediated bone resorption has been reported for these patients, the most notable observation among patients with T2DM is the reduction in bone formation from mostly dysfunction in osteoblast differentiation and survival. Studies have shown that obesity and T2DM are associated with increased adipogenesis which is most likely at the expense of reduced osteogenesis and myogenesis considering that adipocytes, osteoblasts, and myoblasts originate from the same progenitor cells. Furthermore, emerging data point to an inter-relationship between bone and metabolic homeostasis suggesting that these physiologic processes could be under the control of common regulatory pathways. Thus, this review aims to explore the complex mechanisms involved in lineage differentiation and their effect on bone pathophysiology in patients with obesity and T2DM along with an examination of potential novel pharmacological targets or a re-evaluation of existing drugs to improve bone homeostasis.

Indexed as

Diabetes Mellitus, Type 2Fractures, BoneAgedBone and BonesBone DensityHumansObesityOsteogenesisadipogenesisdiabetesmyogenesisobesityosteogenesis

Identifiers

PMID37576965
PMCPMC10422976
OpenAlexW4385387790

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.